WATCH LIVE: Investing.com reveals the top 10 stock picks for 2026
DUBLIN - Investment firm Geode Capital Management, LLC has disclosed a 2.24% ownership stake in Avadel Pharmaceuticals plc, according to a regulatory filing published Monday.
The filing, submitted to the Irish Takeover Panel, reveals that Geode Capital holds 2,194,692 ordinary shares in the pharmaceutical company as of November 28, 2025.
The disclosure also details a recent transaction in which Geode purchased 467 additional Avadel shares at a price of $21.49 per share.
The filing was made in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires disclosure of positions representing 1% or more of a company’s securities during an offer period.
Geode Capital, a global investment management firm, indicated in the filing that it does not have any cash-settled derivatives, stock-settled derivatives, or other arrangements related to Avadel securities.
The disclosure comes amid potential takeover activity involving Avadel Pharmaceuticals, though the filing does not provide details about any specific offers or potential acquirers.
Avadel Pharmaceuticals is a specialty pharmaceutical company that focuses on developing medications for central nervous system disorders.
The information was disclosed through a Form 8.3 filing, which is required when a person holds interests in relevant securities representing 1% or more during an offer period.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.